BRD2 and cancer: For a comprehensive evaluation of NAT transcript levels in cancer, we examined RNA-Seq data from tumour and adjacent normal tissue in the TCGA pan-cancer study, setting the significance threshold at 1.5-fold-change and p < 0.01 (Figure 3A).